Clinuvel Pharmaceuticals Limited (ASX: CUV)
Health Care · Biotechnology · AU
AU$10.60
+2.71% today · -19.8% 1Y
Clinuvel Pharmaceuticals Limited (ASX: CUV) operates in the Biotechnology industry within the Health Care sector. The company is valued at $382.41M and employs 16 people.
Over the last twelve months the share price has lost 19.8%, trading between 8.35 and 14.00.
Tweenvest scores Clinuvel Pharmaceuticals Limited across four factors: quality 82/100, value 75/100, growth 61/100, dividend 48/100. Its strongest factor is quality.
CUV price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $382.41M
- Revenue (TTM)
- $64.24M
- P/E
- 16.47
- EPS
- 0.64
- Dividend yield
- 0.48%
- Beta (5Y)
- 0.57
- 52-week high
- AU$14.00
- 52-week low
- AU$8.35
- Avg volume (3M)
- —
- Shares outstanding
- 50.43M
- Employees
- 16
- Next earnings
- —
About Clinuvel Pharmaceuticals Limited
Clinuvel Pharmaceuticals Limited is a biopharmaceutical company focused on the development and commercialization of treatments for patients battling genetic, metabolic, and life-threatening conditions. Its reach extends across Australia, Europe, the United States, Switzerland, and other global markets. The company's flagship drug, SCENESSE, serves as a systemic photoprotective treatment intended to prevent phototoxicity in adult patients diagnosed with erythropoietic protoporphyria (EPP). Clinuvel's development pipeline includes CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which promotes prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Additionally, Clinuvel Pharmaceuticals has partnered with HK Winhealth Pharma Group Co. Limited for a named patient program in the People's Republic of China, enabling the treatment of EPP patients with SCENESSE. Founded in 1987, the company's corporate headquarters are situated in Melbourne, Australia.
- ISIN
- AU000000CUV3
- Founded
- 1999
- Listed since
- Feb 11, 2001
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.